Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03017326 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Paediatric Hepatic International Tumour Trial

Study acronym: PHITT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 1, 2026 to Dec 31, 2026
    • Study completion date: Aug 1, 2027 to Dec 2027
    v10
  2. Primary completion date: Dec 2024 to Aug 1, 2026v9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 31 to 32
    • Study completion date: Dec 2025 to Aug 1, 2027
    • Collaborators revised (22)
  3. Enrollment target: 300 to 450
    • Study sites: 2 to 31
    • Collaborators: 8 to 22
    v8
  4. Primary completion date: Dec 2022 to Dec 2024
    • Study completion date: Dec 2022 to Dec 2025
    v7
  5. 2 versions Re-verified since Jul 4, 2019, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of May 2017 to Aug 24, 2017
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Start date: Jan 2017 to May 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
Trial Details
NCT Number NCT03017326
Lead Sponsor University of Birmingham
Collaborators: Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University, Experimental Cancer Medicine Centres, XenTech, Evry
Conditions
(from sponsor)		 Hepatoblastoma, Carcinoma, Hepatocellular
Related terms Carcinoma, Hepatocellular, Hepatoblastoma
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov